Clinical trials and rare diseases: a way out of a conundrum, BMJ, vol.311, pp.1621-1626, 1995. ,

Strategy for randomised clinical trials in rare cancers, BMJ, vol.327, pp.47-56, 2003. ,

, Guideline on clinical trials in small populations. Comittee for medicinal products for human use (CHMP), European Medical Agency, 2006.

Small sample sizes in clinical trials: a statistician's perspective, Clin Investig, vol.2, pp.655-662, 2012. ,

Statistical challenges in the evaluation of treatments for small patient populations, Sci Transl Med, vol.5, pp.178-181, 2013. ,

Methodology of clinical trials for rare diseases, Best Pract Res Clin Rheumatol, vol.28, pp.247-62, 2014. ,

How do you design randomised trials for smaller populations? A framework, BMC Med, vol.14, p.183, 2016. ,

on an action in the field of rare diseases, 2009. ,

Rare cancers: a sea of opportunity, Lancet Oncol, vol.17, pp.52-61, 2016. ,

The value of research collaborations and consortia in rare cancers, Lancet Oncol, vol.17, pp.62-71, 2016. ,

URL : https://hal.archives-ouvertes.fr/hal-01791267

Research methods to change clinical practice for patients with rare cancers, Lancet Oncol, vol.17, pp.70-80, 2016. ,

Threshold-crossing": a useful way to establish the counterfactual in clinical trials?, Clin Pharmacol Ther, vol.100, pp.699-712, 2016. ,

Guidance for industry and FDA staff: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials, 2016. ,

Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. Guidance for Industry, 2017. ,

The combination of randomized and historical controls in clinical trials, J Chronic Dis, vol.29, pp.175-88, 1976. ,

Power prior distributions for regression models, Stat Sci, vol.15, pp.46-60, 2000. ,

A note on the power prior, Stat Med, vol.28, pp.3562-3568, 2009. ,

Summarizing historical information on controls in clinical trials, Clin Trials Lond Engl, vol.7, pp.5-18, 2010. ,

Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials, Biometrics, vol.67, pp.1047-56, 2011. ,

Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models, Bayesian Anal, vol.7, pp.639-74, 2012. ,

Robust meta-analytic-predictive priors in clinical trials with historical control information, Biometrics, vol.70, pp.1023-1055, 2014. ,

Addressing potential prior-data conflict when using informative priors in proof-of-concept studies, Pharm Stat, vol.15, pp.28-36, 2016. ,

Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information, J Biopharm Stat, vol.26, pp.1056-66, 2016. ,

Adaptive power priors with empirical Bayes for clinical trials, Pharm Stat, vol.16, pp.349-60, 2017. ,

Extrapolation of efficacy and other data to support the development of new medicines for children: a systematic review of methods, Stat Methods Med Res, p.0962280216631359, 2016. ,

Use of prior information for Bayesian evaluation of bridging studies, J Biopharm Stat, vol.17, pp.109-130, 2007. ,

A Bayesian approach for inference from a bridging study with binary outcomes, J Biopharm Stat, vol.22, pp.935-51, 2012. ,

Robust Bayes and empirical Bayes analysis with $_\epsilon$-contaminated priors, Ann Stat, vol.14, pp.461-86, 1986. ,

Using prior distributions to synthesize historical evidence: comments on the Goodman-Sladky case study of IVIg in Guillain-Barré syndrome, Clin Trials Lond Engl, vol.2, pp.364-78, 2005. ,

Bayesian survival analysis in clinical trials: what methods are used in practice?, Clin Trials, vol.14, pp.78-87, 2017. ,

Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative, Eur J Cancer Oxf Engl, vol.51, pp.271-281, 1990. ,

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, Lancet Oncol, vol.17, pp.1070-80, 2016. ,

URL : https://hal.archives-ouvertes.fr/inserm-01702092

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's oncology group, J Clin Oncol, vol.26, pp.633-641, 2008. ,

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's oncology group, Cancer, vol.115, pp.5339-5387, 2009. ,

Sample-size formula for the proportional-hazards regression model, Biometrics, vol.39, pp.499-503, 1983. ,

The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time, Biometrika, vol.68, pp.311-316, 1981. ,

Monte Carlo sampling methods using Markov chains and their applications, Biometrika, vol.57, pp.97-109, 1970. ,

R Foundation for statistical computing. R: A Language and Environment for Statistical Computing, 2016. ,

Markov chain Monte Carlo in R, J Stat Softw, vol.42, 2011. ,

LearnBayes: functions for learning Bayesian inference, 2014. ,

The inclusion of historical control data may reduce the power of a confirmatory study, Stat Med, vol.30, pp.1329-1367, 2011. ,

Use of historical control data for assessing treatment effects in clinical trials, Pharm Stat, vol.13, pp.41-54, 2014. ,

Including historical data in the analysis of clinical trials: is it worth the effort?, Stat Methods Med Res, p.962280217694506, 2017. ,

Using historical control information for the design and analysis of clinical trials with overdispersed count data, Stat Med, vol.32, pp.3609-3631, 2013. ,

The use of power prior distributions for incorporating historical data into a Bayesian analysis. Technical report: Dep Health Care Policy Harv Med Sch, 2009. ,

Incorporation of historical data in the analysis of randomized therapeutic trials, Contemp Clin Trials, vol.32, pp.848-55, 2011. ,

Flexible parametric proportional-hazards and proportionalodds models for censored survival data, with application to prognostic modelling and estimation of treatment effects, Stat Med, vol.21, pp.2175-97, 2002. ,

Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, Biometrics, vol.68, pp.578-86, 2012. ,

Finding alternatives to the dogma of power based sample size calculation: is a fixed sample size prospective meta-experiment a potential alternative, PLoS One, vol.11, p.158604, 2016. ,